Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Mar 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying chronic hand eczema, a skin condition that can cause itching, redness, and swelling on the hands. Researchers are using advanced techniques to better understand the immune system's role in this condition, which may help identify new ways to treat it. The trial is currently recruiting participants who are between 18 and 65 years old and have had hand eczema for at least three months or have experienced two or more flare-ups in the past year. People with atopic dermatitis affecting their hands, as long as it doesn’t cover more than 30% of their body, may also qualify.

If you decide to participate, you'll undergo tests to help researchers learn more about the immune processes involved in your eczema. However, there are some restrictions on medications: you cannot have taken certain treatments like immunosuppressants or long-term corticosteroids recently. This study aims to gather valuable information that could lead to better treatments for those suffering from chronic hand eczema, so your involvement could make a difference in understanding this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients affected with chronic hand eczema of endogenous and/or exogenous origin, age from 18 to 65 years
• • Patients affected with eczema located on the hands for at least 3 months or with ≥ 2 disease flare-ups in the last year.
• • Patients affected with atopic dermatitis affecting the hands and other areas of the body, provided the eczema lesions involve less than 30% of the body surface area.
• Exclusion Criteria:
• • Concurrent or previous treatment with immunosuppressants, except for short courses of systemic corticosteroids (less than one month of continuous treatment), or biologic agents that may affect the clinical aspects or progression of chronic hand eczema.
• • Patients who have received systemic corticosteroids within one month prior to enrollment in the study.
• • Patients using topical corticosteroids or calcineurin inhibitors within one week of study enrollment (this time frame is considered to provide a good balance between potential residual pharmacological effects and ethical considerations).
• • Patients with chronic hand eczema of mixed etiology (e.g., allergic and atopic) or those considered "etiologically unclassifiable" will not be included in the data analysis.